What Happened?
A number of stocks fell in the afternoon session after the renewed Iran-UAE incident reignited concerns about input cost inflation and global supply chain disruption.
Med-tech manufacturing relies heavily on petroleum-derived plastics, resins, and sterile packaging, and the surge in WTI crude back above $105 directly threatened the cost of goods sold across catheters, syringes, IV sets, and surgical disposables.
Furthermore, the sector faces dual pressure from rising freight and air-cargo costs as global shipping reroutes around the Middle East, and from hospital customers who tend to defer elective procedures and capital equipment purchases when macro uncertainty rises and consumer healthcare deductibles bite. With Treasury yields climbing and the Fed expected to stay on hold deeper into 2026, the discount rate applied to long-duration med-tech earnings streams also moves against the group.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Medical Devices & Supplies - Diversified company Neogen (NASDAQ: NEOG) fell 4.7%. Is now the time to buy Neogen? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Diversified company Baxter (NYSE: BAX) fell 3.2%. Is now the time to buy Baxter? Access our full analysis report here, it’s free.
Zooming In On Neogen (NEOG)
Neogen’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 27 days ago when the stock gained 4.8% on the news that the government announced a surprise increase in payment rates for Medicare Advantage plans. This change raises the revenue that insurance companies receive per patient from federal funds without increasing their costs. This is projected to improve profit margins for major providers like UnitedHealth and Humana.
Neogen is up 29.2% since the beginning of the year, but at $9.05 per share, it is still trading 20.2% below its 52-week high of $11.33 from February 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Neogen’s shares 5 years ago would now be looking at only $190.38.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
